Upadacitinib effectively suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn's disease tissue.
Interleukin-13 receptor alpha 2 (IL13RA2) is highly expressed in intestinal inflammation-associated fibroblasts (IAFs) and is associated with anti-tumor necrosis factor alpha (TNF-α) therapy resistance in inflammatory bowel disease (IBD). Because IL13RA2 inhibition ameliorates experimental colitis in mice, we investiga...